Creative Diagnostics Expands Response to COVID-19 to Recombinant SARS-CoV-2 RBD Mutants

by Thomas Schmitt Contributor

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   617    Comments 0

The global cases of COVID-19 are expected to soar unceasingly, and to facilitate related research worldwide, Creative Diagnostics integrates recombinant SARS-CoV-2 RBD mutants to its SARS-CoV-2 products and services.

As COVID-19 is still spreading all over the world, the global confirmed cases have jumped to 9 million. It only took 6 days for the pandemic total to rise from 8 million to 9 million cases. However, due to the complexity of SARS-CoV-2, there are currently no vaccines or drugs available for the prevention and treatment of COVID-19, showing an emergent need for effective prevention and treatment measures.

Since the beginning of the outbreak, Creative Diagnostics has been dedicated to providing related products and services to facilitate SARS-CoV-2 research, and now it has expanded the response to include recombinant SARS-CoV-2 RBD mutants.

The receptor binding domain (RBD) of the SARS-CoV-2 Spike protein plays the key role in the tight binding to human ACE2 for viral entry. Through polymorphism analysis and divergence analysis, research has shown that the RBD sequence is as diverse as other regions of the S protein. Containing important antigenic epitopes, frequent mutations in RBD, especially the change of amino acid properties, may weaken the binding affinity of the antibody raised against the prototype strain, which may lead to the decline of vaccine efficacy.

Creative Diagnostics now offers novel products of SARS-CoV-2 Spike/RBD mutants expressed in HEK293 cells, covering recombinant SARS-CoV-2 Spike RBD (V367F), recombinant SARS-CoV-2 S protein RBD (R408I), recombinant SARS-CoV-2 Spike S1 (D614G) Protein, recombinant SARS-CoV-2 S protein (R683A, R685A) active trimer (MALS verified), etc. Being post-translationally modified (glycosylation and phosphorylation), these antigens closely resemble the native viral proteins, and will overcome specificity issues in COVID-19 serology assays.

“The research of Los Alamos National Laboratory shows that a major D614G mutation on SARS-CoV-2 Spike has emerged in European countries,” said a senior scientist at Creative Diagnostics, “and this D614G mutation may make the virus more transmissive. So, it’s of great importance to understand the biology of this variant, especially concerning the research and development of vaccine and drug.”

With leading technologies, professional in-house experts as well as extensive experience in other coronaviruses such as MERS-CoV and SARS-CoV, Creative Diagnostics spares no effort to supporting SARS-CoV-2 research. Apart from the aforementioned recombinant SARS-CoV-2 RBD mutants, SARS-CoV-2 immunoassay kits, human ACE2 stable cell line, and matched antigen pair for SARS-CoV-2 serology test development are also available at Creative Diagnostics.

If you want to know more information about related products or services, please email to or visit the official website on


About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, aiming to provide a trusted source for all researchers’ assay development and manufacturing needs.

Subscribe to Newsletter
Share this:              


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *